Bexarotene: a promising anticancer agent
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Retinoids are biologically active derivatives of vitamin A, which play essential roles in embryonic or adult cell behavior modulating cell proliferation, differentiation and apoptosis. The biologic effects of retinoids are mediated by two distinct families of intracellular receptors: retinoid acid receptors (RARs)-α, -β and -γ and retinoid X receptors (RXR)-α, -β and -γ. Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it a promising chemopreventive agent against cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to its differentiating effect, it has also been reported to inhibit the proliferation of lymphoma and lung, liver and solid ovarian tumors [7,185,193].”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [7]
In the citing paper
“Apart from the well-known indications in hypovitaminosis and skin diseases, retinoids have been successfully used in treating cancer”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [7]
In the citing paper
“bexarotene can selectively bind to RXR and modulate gene expression and cell proliferation and has been successfully used in treating cutaneous T-cell lymphoma”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [7]
Citations
Cites
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Tamm, I., Wang, Y., Sausville, E. A., Scudiero, D. A., Vigna, N. J., Oltersdorf, T., & Reed, J. C. (1998) · PubMed · Cited by 1,397
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · cited 1×
“(Targretin/Ligand Pharmaceuticals) Launched: NSCLC, CTCL [ 11 ]”
Embryonic retinoic acid synthesis is essential for early mouse post-implantation development
Niederreither, K., Subbarayan, V., Dollé, P., & Chambon, P. (1999) · Nature Genetics · doi:10.1038/7788 · Cited by 1,077
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Duvic, M. A., Martín, Á. G., Kim, Y. H., Olsen, E. A., Wood, G. S., Crowley, C., & Yocum, R. C. (2001) · PubMed · Cited by 489
Clinging to life: cell to matrix adhesion and cell survival
Reddig, P. J., & Juliano, R. L. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-5134-3 · Cited by 440
NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells
Bentires-Alj, M., Barbu, V., Fillet, M., Chariot, A., Relic, B., Jacobs, N., Gielen, J., Merville, M.-P., & Bours, V. (2003) · Oncogene · doi:10.1038/sj.onc.1206056 · Cited by 430
Retinoids in cancer chemoprevention
Lotan, R. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801164 · Cited by 423
Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids
Boehm, M. F., Zhang, L., Badea, B. A., White, S. K., Mais, D. E., Berger, E., Suto, C. M., Goldman, M. E., & Heyman, R. A. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00044a014 · Cited by 370
A new class of retinoids with selective inhibition of AP-1 inhibits proliferation
Fanjul, A., Dawson, M. I., Hobbs, P. D., Jong, L., Cameron, J. F., Harlev, E., Graupner, G., Lu, X.-P., & Pfahl, M. (1994) · Nature · doi:10.1038/372107a0 · Cited by 313
Zhang, C., Hazarika, P., Ni, X., Weidner, D. A., & Duvic, M. A. (2002) · PubMed · Cited by 223
Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism
Langenfeld, J., Kiyokawa, H., Sekula, D., Boyle, J., & Dmitrovsky, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12070 · Cited by 202
Wu, K., Zhang, Y., Xu, X., Hill, J. L., Celestino, J., Kim, H.-T., Mohsin, S. K., Hilsenbeck, S. G., Lamph, W. W., Bissonette, R., et al. (2002) · PubMed · Cited by 166
Kuo, M. T. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2095 · Cited by 163
All- retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia
Fenaux, P., Chomienne, C., & Degos, L. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90002-2 · Cited by 152
Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer
Niles, R. M. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00436-6 · Cited by 151
Bexarotene therapy for mycosis fungoides and Sézary syndrome
Abbott, R. A., Whittaker, S. J., Morris, S. L., Russell-Jones, R., Hung, T., Bashir, S. J., & Scarisbrick, J. J. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09037.x · Cited by 124
Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer
Esteva, F. J., Glaspy, J., Baidas, S., Laufman, L., Hutchins, L., Dickler, M., Tripathy, D., Cohen, R., DeMichele, A., Yocum, R. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.068 · Cited by 115
Clinical trials with retinoids for breast cancer chemoprevention
Zanardi, S., Serrano, D., Argusti, A., Barile, M., Puntoni, M., & DeCensi, A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00938 · Cited by 115
Foss, F., Demierre, M. F., & DiVenuti, G. (2005) · Blood · doi:10.1182/blood-2004-11-4570 · Cited by 114
Altucci, L., Rossin, A., Hirsch, O., Nebbioso, A., Vitoux, D., Wilhelm, E., Guidez, F., De Simone, M., Schiavone, E. M., Grimwade, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3569 · Cited by 114
The Retinoids and Cancer Prevention Mechanisms
Dragnev, K. H., Rigas, J. R., & Dmitrovsky, E. (2000) · The Oncologist · doi:10.1634/theoncologist.5-5-361 · Cited by 112
Blumenschein, G. R., Khuri, F. R., von Pawel, J., Gatzemeier, U., Miller, W. H., Jotte, R. M., Treut, J. H. L., Sun, S.-L., Zhang, J. K., Dziewanowska, Z. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2689 · Cited by 95
Ramlau, R., Zatloukal, P., Jassem, J., Schwarzenberger, P. O., Орлов, С. В., Gottfried, M., Pereira, J. R., Temperley, G., Negro‐Vilar, R., Rahal, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2614 · Cited by 93
Straus, D. J., Duvic, M., Kuzel, T., Horwitz, S., Demierre, M., Myskowski, P., & Steckel, S. (2007) · Cancer · doi:10.1002/cncr.22596 · Cited by 91
A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer
Dragnev, K. H., Petty, W. J., Shah, S. J., Lewis, L. D., Black, C. C., Memoli, V., Nugent, W. C., Hermann, T., Negro-Vilar, A., Rigas, J. R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1836 · Cited by 90
Kizaki, M., Dawson, M., Heyman, R. A., Elster, E. A., Roberta Morosetti, A., Pakkala, S., Dl, C., Ueno, H., Chao, W., Morikawa, M., et al. (1996) · Blood · doi:10.1182/blood.v87.5.1977.1977 · Cited by 84
Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer
Cesario, R. M., Stone, J. K., Yen, W.-C., Bissonnette, R. P., & Lamph, W. W. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.09.010 · Cited by 84
UBE1L causes lung cancer growth suppression by targeting cyclin D1
Feng, Q., Sekula, D., Guo, Y., Liu, X., Black, C. C., Galimberti, F., Shah, S. J., Sempere, L. F., Memoli, V., Andersen, J. B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0753 · Cited by 82
Novel treatment of chronic severe hand dermatitis with bexarotene gel
Hanifin, J. M., Stevens, V., Sheth, P. B., & Breneman, D. (2004) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05729.x · Cited by 81
PI3K/Akt inhibition modulates multidrug resistance and activates NF-κB in murine lymphoma cell lines
García, M. G., Alaniz, L. D., Cordo Russo, R. I., Alvarez, E., & Hajos, S. E. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.06.010 · Cited by 77
Tooker, P., Yen, W.-C., Ng, S., Negro-Vilar, A. F., & Hermann, T. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4495 · Cited by 72
Yen, W.-C., Corpuz, M. R., Prudente, R. Y., Cooke, T. A., Bissonnette, R. P., Negro-Vilar, A., & Lamph, W. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0979 · Cited by 71
Angiogenic molecules and cancer metastasis.
Kumar, R., & Fidler, I. J. (1998) · PubMed · Cited by 69
Antifungal drugs-an introduction
Rj, H. (1990) · Journal of Dermatological Treatment · doi:10.3109/09546639009089020 · Cited by 61
Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene
Rigas, J. R., & Dragnev, K. H. (2005) · The Oncologist · doi:10.1634/theoncologist.10-1-22 · Cited by 60
Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma
Nieto-Rementería, N., Pérez-Yarza, G., Boyano, M. D., Apraiz, A., Izu, R., Díaz-Pérez, J. L., & Asumendi, A. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08931.x · Cited by 59
Talpur, R., Vu, J., Bassett, R. L., Stevens, V., & Duvic, M. A. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.02.037 · Cited by 59
Bexarotene and Erlotinib for Aerodigestive Tract Cancer
Dragnev, K. H., Petty, W. J., Shah, S., Biddle, A., Desai, N. B., Memoli, V., Rigas, J. R., & Dmitrovsky, E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9521 · Cited by 59
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma
Liu, Y. Y., Stokkel, M. P., Pereira, A. M., Corssmit, E. P., Morreau, H. A., Romijn, J. A., & Smit, J. W. A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02123 · Cited by 59
Jones, D. R., Broad, R. M., Comeau, L., Parsons, S. J., & Mayo, M. W. (2002) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2002.118684 · Cited by 57
Bexarotene Is a New Treatment Option for Lymphomatoid Papulosis
KRATHEN, R. A., Ward, S., & Duvic, M. A. (2003) · Dermatology · doi:10.1159/000068451 · Cited by 56
Yen, W.-C., Prudente, R. Y., Corpuz, M. R., Negro-Vilar, A., & Lamph, W. W. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602995 · Cited by 56
Yen, W.-C., Prudente, R. Y., & Lamph, W. W. (2004) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1426-5 · Cited by 53
Yen, W.-C., & Lamph, W. W. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0018 · Cited by 48
Yen, W.-C., & Lamph, W. W. (2005) · The Prostate · doi:10.1002/pros.20347 · Cited by 48
Papadavid, E., Antoniou, C., Nikolaou, V., Siakantaris, M. P., Vassilakopoulos, T. P., Stratigos, A., Stavrianeas, N. G., & Katsambas, A. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809030-00005 · Cited by 44
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
Tsai, D. E., Luger, S. M., Andreadis, C. B., Vogl, D. T., Kemner, A., Potuzak, M., Goradia, A., Loren, A. W., Perl, A. E., Schuster, S. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5185 · Cited by 38
Nakajima, Y., Madhyastha, R., & Maruyama, M. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009787313846 · Cited by 34
Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides
Lokitz, M. L., & Wong, H. K. (2007) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2007.00315.x · Cited by 32
Uray, I. P., Shen, Q., Seo, H.-S., Kim, H., Lamph, W. W., Bissonnette, R. P., & Brown, P. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804721200 · Cited by 30
Steinhoff, M., Beyer, M., Roewert-Huber, J., Lukowsky, A., Assaf, C., & Sterry, W. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.07.012 · Cited by 28
Rizvi, N. A., Hawkins, M., Eisenberg, P. D., Yocum, R. C., & Reich, S. D. (2001) · Clinical Lung Cancer · doi:10.3816/clc.2001.n.005 · Cited by 26
Kannangara, A. P., Levitan, D. A., & Fleischer, A. B. (2008) · Journal of Dermatological Treatment · doi:10.1080/09546630802562427 · Cited by 26
A Phase I Study of Bexarotene and Rosiglitazone in Patients with Refractory Cancers
Read, W. L., Baggstrom, M. Q., Fracasso, P. M., & Govindan, R. (2008) · Chemotherapy · doi:10.1159/000140468 · Cited by 25
Retinoids in lung cancer chemoprevention and treatment
Toma, S., Raffo, P., Isnardi, L., & Palumbo, R. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_5.s95 · Cited by 25
Oral Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma
Wong, S. (2001) · Annals of Pharmacotherapy · doi:10.1177/106002800103500903 · Cited by 21
Retinoids in cancer prevention
Pastorino, U. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90827-3 · Cited by 20
Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB
D’Acunto, C., Gurioli, C., & Neri, I. (2009) · Journal of Dermatological Treatment · doi:10.3109/09546630903103980 · Cited by 20
Modulation by bexarotene of mRNA expression of genes in mouse lung tumors
Alyaqoub, F. S., Liu, Y., Tao, L., Steele, V. E., Lubet, R. A., & Pereira, M. A. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20383 · Cited by 16
Ying, S., Seal, S., Abbasi, N., Hockenbery, D. M., Kiem, H., Li, X., Pagel, J. M., Gopal, A. K., & Deeg, H. J. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701242358 · Cited by 16
Eichele, G. (1999) · Nature Genetics · doi:10.1038/7665 · Cited by 15
Phase II clinical trial of bexarotene gel 1% in psoriasis.
Breneman, D., Sheth, P. B., Berger, V., Naini, V., & Stevens, V. (2007) · PubMed · Cited by 12
A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma.
Bedikian, A. Y., Plager, C., Papadopoulos, N., Ellerhorst, J. A., Smith, T., & Benjamin, R. S. (2000) · Oncology Reports · doi:10.3892/or.7.4.883 · Cited by 7
Treatment of parapsoriasis with bexarotene 1% gel
Lessin, S. R., Ross, E. A., & Wu, H. G. (2008) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2008.03740.x · Cited by 6
Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB
D’Acunto, C., Gurioli, C., & Neri, I. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630903103980 · Cited by 3
Brown, P. H., Subbaramaiah, K., Salmon, A. P., Baker, R., Newman, R. A., Yang, P., Zhou, X. K., Bissonette, R., Dannenberg, A. J., & Howe, L. R. (2008) · PubMed Central · doi:10.1158/1940-6207.capr-08-0021 · Cited by 2
Research works printed but not linked: 1
- Yocum RC, Miller VA, Warrell RP et al (2001) Long-term followup of patients with advanced non-small cell lung cancer treated with oral bexarotene. Proc Am Soc Clin Oncol 20:267
Cited by
Carazo, A., Macáková, K., Matoušová, K., Krčmová, L. K., Protti, M., & Mladěnka, P. (2021) · Nutrients · doi:10.3390/nu13051703 · Cited by 461
“In addition to its differentiating effect, it has also been reported to inhibit the proliferation of lymphoma and lung, liver and solid ovarian tumors [7,185,193].”
BackgroundRetinoid pathway and cancer therapeutics
Bushue, N., & Wan, Y.-J. Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.003 · Cited by 373
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
“The mechanisms of anticancer are inhibition of cell cycle progression, inhibition of angiogenesis and metastasis [24].”
Retinoid X receptors in macrophage biology
Rőszer, T., Menéndez-Gutiérrez, M. P., Cedenilla, M., & Ricote, M. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.04.004 · Cited by 137
Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR
Hiebl, V., Ladurner, A., Latkolik, S., & Dirsch, V. M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.003 · Cited by 134
Metadata
- Authors
- Qu, L., & Tang, X.
- Affiliations
- Zhejiang University (CN)
- Corresponding author
- Tang, Xiuwen
- ORCID
- Tang, Xiuwen
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2009-09-24
- Volume
- 65
- Issue
- 2
- Pages
- 201-205
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W1988329373
- Cited by
- 78
- References
- 68
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 1 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 6 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 6 · 2013: 9 · 2012: 5
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- bexarotene, retinoids, retinoid X receptor agonist, apoptosis, cell differentiation, cell cycle arrest, multidrug resistance, angiogenesis inhibition, metastasis, chemoprevention
- MeSH terms
- Bexarotene, Cell Cycle, Cell Differentiation, Humans, Neoplasm Metastasis, Tetrahydronaphthalenes, Anticarcinogenic Agents, Apoptosis, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Retinoid X Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.